Sows postpartum dysgalactia syndrome therapy with ceftiofur based preparation

The aim of the study is to conduct a clinical assessment of the therapeutic efficacy of Ceftonit® Forte in sows with postpartum dysgalactia syndrome. The material for the study was 30 sick Yorkshire and Landrace sows or their crossbreeds, who were diagnosed with postpartum dysgalactia syndrome. According to the principle, the animals were divided into experimental (n=15) and control (n=15) groups. The sows of the experimental group were treated with Ceftonit® Forte: the drug was administered once or twice (in case of recurrence of signs of the disease) intramuscularly, at a dose of 1 ml/40 kg of body weight. For the treatment of animals of the control group, the scheme adopted in the farm was used: an antimicrobial drug based on amoxicillin trihydrate - intramuscularly at a dose of 1 ml/10 kg of body weight, at least three times with an interval of 48 hours (if necessary, the course of antibiotic therapy was extended until the sick animal recovered completely). Before antibiotic therapy, the microbial background of the vagina, colostrum and milk of sows with clinical signs of postpartum dysgalactia syndrome was determined. The results of the study showed a high therapeutic efficacy of Ceftonit® Forte with its differentiated single or double (according to the clinical situation) application to sows with postpartum dysgalactia syndrome. By the time of weaning of piglets, the final therapeutic efficacy of Ceftonit® Forte reaches 100 % with an average frequency of administration of the drug - 1.13±0.29 times. In this case, the duration of the period from the beginning of treatment to complete recovery is on average 7.87±1.56 days. Ceftonitis® Forte is effective against microorganisms of the genera Escherichia, Streptococcus, Staphylococcus, Enterobacter, etc., which are the main causative agents of endometritis and mastitis associated with the development of postpartum dysgalactia syndrome.